Last reviewed · How we verify
NWRD06 administered by electroporation
At a glance
| Generic name | NWRD06 administered by electroporation |
|---|---|
| Sponsor | Newish Technology (Beijing) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- NWRD06 DNA Plasmid for HCC After Curative Resection. (PHASE2)
- NWRD06 DNA Plasmid for HCC After Radical Resection (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: